Related Experiment Videos
Viral load as a surrogate end point in HIV disease
1Department of Pharmacy Practice, College of Pharmacy, Ferris State University, Lansing, MI, USA. smithc@ferris.edu
The Annals of Pharmacotherapy
|February 19, 2002
Summary
Viral load is a key indicator for monitoring HIV disease and treatment effectiveness. However, it does not fully explain all clinical improvements seen with antiretroviral therapy.
Area of Science:
- Virology
- Immunology
- Clinical Medicine
Background:
- Viral load is an emerging biomarker for monitoring HIV disease progression and antiretroviral therapy (ART).
- Understanding the role of viral load as a surrogate endpoint is crucial for evaluating treatment efficacy.
Purpose of the Study:
- To examine the role of viral load as a surrogate endpoint for HIV disease progression and mortality.
- To assess the extent to which viral load changes explain the clinical benefits of ART.
Main Methods:
- A comprehensive literature search of MEDLINE (1990-March 2001) was performed.
- Relevant articles were cross-referenced to identify additional studies.
- Data from randomized controlled trials and descriptive studies were synthesized.
Main Results:
- Both baseline and time-dependent changes in viral load predict HIV disease progression and death.
- Disease progression accelerates when viral load exceeds 10,000 copies/mL.
- AIDS and death are primarily observed in patients with viral loads greater than 100,000 copies/mL.
- Viral load changes do not fully account for the observed treatment effects of ART.
Conclusions:
- Viral load is a clinically significant surrogate endpoint for HIV disease management and ART monitoring.
- While important, viral load changes alone do not explain the complete clinical improvement associated with ART.
- Viral load monitoring is valuable, but its limitations in fully capturing treatment effects should be acknowledged.